A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
accelerate development of therapies across the spectrum 
of rare diseases and conditions and facilitate patient 
access to such therapies, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Speeding Therapy Ac-
4
cess Today Act of 2021’’. 
5
SEC. 2. TABLE OF CONTENTS. 
6
The table of contents of this Act is as follows: 
7
Sec. 1. Short title. 
Sec. 2. Table of contents. 
Sec. 3. Intercenter Institute on Rare Diseases and Conditions. 
01:39 May 07, 2021
H1730
2 
•HR 1730 IH
Sec. 4. Rare Disease and Condition Drug Advisory Committee. 
Sec. 5. Grants and contracts for development of drugs for rare diseases and 
conditions. 
SEC. 3. INTERCENTER INSTITUTE ON RARE DISEASES AND 
1
CONDITIONS. 
2
(a) ESTABLISHMENT REQUIRED.—The first sentence 
3
of section 1014(a) of the Federal Food, Drug, and Cos-
4
metic Act (21 U.S.C. 399g(a)) is amended by inserting 
5
‘‘, at least one of which shall be focused on rare diseases 
6
and conditions’’ before the period at the end of the sen-
7
tence. 
8
(b) TIMING OF ESTABLISHMENT.—Subsection (c) of 
9
section 1014 of the Federal Food, Drug, and Cosmetic 
10
Act (21 U.S.C. 399g) is amended to read as follows: 
11
‘‘(c) TIMING.—Not later than the date that is 1 year 
12
after the date of enactment of the Speeding Therapy Ac-
13
cess Today Act of 2021, the Secretary shall establish, in 
14
accordance with this section and section 529B, an Insti-
15
tute under subsection (a) focused on rare diseases and 
16
conditions, to be known as the Intercenter Institute on 
17
Rare Diseases and Conditions.’’. 
18
(c) RESPONSIBILITIES.—Subchapter B of chapter V 
19
of the Federal Food, Drug, and Cosmetic Act (relating 
20
to drugs for rare diseases or conditions) is amended by 
21
inserting after section 529A of such Act (21 U.S.C. 360ff– 
22
1) the following new section: 
23
01:39 May 07, 2021
H1730
3 
•HR 1730 IH
‘‘SEC. 529B. INTERCENTER INSTITUTE ON RARE DISEASES 
1
AND CONDITIONS. 
2
‘‘(a) RESPONSIBILITIES.—In addition to carrying out 
3
activities listed in section 1014(a), the Intercenter Insti-
4
tute on Rare Diseases and Conditions shall— 
5
‘‘(1) serve as the Food and Drug Administra-
6
tion’s coordinating office for engagement with rare 
7
disease and condition stakeholders, complementing 
8
but not supplanting engagement activities between 
9
stakeholders and the review divisions; 
10
‘‘(2) build, within the Food and Drug Adminis-
11
tration, knowledge and understanding associated 
12
with the review of medical products to treat rare dis-
13
eases and conditions, including advancements in trial 
14
design, statistical analysis, regulatory science, prod-
15
uct manufacturing, and other topics as determined 
16
by the Secretary; 
17
‘‘(3) implement cross-center rare disease and 
18
condition-focused meetings and policy development; 
19
‘‘(4) coordinate rare disease and condition-spe-
20
cific regulatory science initiatives; 
21
‘‘(5) facilitate stakeholder engagement to the 
22
external community and international regulatory 
23
agencies on rare disease and condition product devel-
24
opment; 
25
01:39 May 07, 2021
H1730
4 
•HR 1730 IH
‘‘(6) establish and implement the Accelerating 
1
Lifesavings Therapies in Treating Ultra-rare Dis-
2
ease Entities Program under subsection (b); and 
3
‘‘(7) establish and carry out the rare disease 
4
and condition third-party payor program under sub-
5
section (d). 
6
‘‘(b) ALTITUDE PROGRAM.— 
7
‘‘(1) IN GENERAL.—The Intercenter Institute 
8
shall establish and implement a program, to be 
9
known as the Accelerating Lifesavings Therapies in 
10
Treating Ultra-rare Disease Entities Program, to 
11
identify and make recommendations to address cur-
12
rent and emerging regulatory science and public pol-
13
icy challenges associated with developing medical 
14
products to treat rare diseases or conditions in an 
15
individual or very small populations. 
16
‘‘(2) ISSUES.—The program under paragraph 
17
(1) shall focus on issues including— 
18
‘‘(A) manufacturing standards for thera-
19
pies described in such paragraph, including in 
20
non-industry settings; 
21
‘‘(B) trial designs and metrics; 
22
‘‘(C) regulatory flexibilities for abbreviated 
23
toxicology studies, overlapping animal studies, 
24
and patient dosing; 
25
01:39 May 07, 2021
H1730
5 
•HR 1730 IH
‘‘(D) regulatory science, chemistry, manu-
1
facturing, and other needs associated with de-
2
veloping such therapies; and 
3
‘‘(E) other issues as determined by the 
4
Secretary. 
5
‘‘(c) PROPOSALS FOR AMENDING LABELS.— 
6
‘‘(1) STAKEHOLDER
GROUP.—Not later than 
7
180 days after the date of enactment of this section, 
8
the Intercenter Institute shall convene a meeting of 
9
stakeholders from the rare disease community, in-
10
cluding patients, caregivers, product manufacturers, 
11
third-party payors, and others, to consider potential 
12
amendments to labels for medical products to treat 
13
rare diseases or conditions approved pursuant to a 
14
pathway under section 506. 
15
‘‘(2) GUIDANCE.—Not later than 90 days after 
16
the date of the meeting under paragraph (1), the 
17
Secretary shall issue guidance to propose changes to 
18
how the labels of medical products to treat rare dis-
19
eases or conditions demonstrate clinical benefits and 
20
reflect relevant scientific data including surrogate 
21
endpoints. 
22
‘‘(d) RARE DISEASE AND CONDITION THIRD-PARTY 
23
PAYOR PROGRAM.— 
24
01:39 May 07, 2021
H1730
6 
•HR 1730 IH
‘‘(1) IN GENERAL.—The Intercenter Institute 
1
shall establish and carry out a voluntary rare disease 
2
and condition early third-party payor feedback pro-
3
gram— 
4
‘‘(A) to inform coverage policies for rare 
5
disease therapies; and 
6
‘‘(B) to inform clinical trial design, patient 
7
engagement, and other data collections. 
8
‘‘(2) PROGRAM REQUIREMENTS.—The program 
9
under paragraph (1) shall— 
10
‘‘(A) facilitate voluntary communication 
11
between sponsors of medical products to treat 
12
rare diseases and conditions and third-party 
13
payors; and 
14
‘‘(B) require participation of the Centers 
15
for Medicare & Medicaid Services with rep-
16
resentation from— 
17
‘‘(i) the Center for Medicare; and 
18
‘‘(ii) the Center for Medicaid and 
19
CHIP Services. 
20
‘‘(3) ANNUAL REPORT.—The Intercenter Insti-
21
tute shall— 
22
‘‘(A) on an annual basis, submit a report 
23
to that Congress on— 
24
01:39 May 07, 2021
H1730
7 
•HR 1730 IH
‘‘(i) the participation within the pro-
1
gram under paragraph (1); and 
2
‘‘(ii) the impacts of the program 
3
under paragraph (1); and 
4
‘‘(B) post each such report on the public 
5
website of the Intercenter Institute. 
6
‘‘(4) BULLETIN
TO
MEDICAID
DIRECTORS.— 
7
Following the approval, clearance, or authorization 
8
by the Food and Drug Administration of a medical 
9
product to treat a rare disease or condition, the Sec-
10
retary shall issue a bulletin to State Medicaid direc-
11
tors containing information to help inform coverage 
12
decisions on the product by State Medicaid and Chil-
13
dren’s Health Insurance programs. 
14
‘‘(e) DEFINITION.—In this section, the terms ‘Inter-
15
center Institute on Rare Diseases and Conditions’ and 
16
‘Intercenter Institute’ refer to the Intercenter Institute on 
17
Rare Diseases and Conditions established pursuant to sec-
18
tion 1014.’’. 
19
SEC. 4. RARE DISEASE AND CONDITION DRUG ADVISORY 
20
COMMITTEE. 
21
Subchapter B of chapter V of the Federal Food, 
22
Drug, and Cosmetic Act is further amended by inserting 
23
after section 529B of such Act, as inserted by section 3, 
24
the following new section: 
25
01:39 May 07, 2021
H1730
8 
•HR 1730 IH
‘‘SEC. 529C. RARE DISEASE AND CONDITION DRUG ADVI-
1
SORY COMMITTEE. 
2
‘‘(a) IN GENERAL.—The Secretary shall establish 
3
and maintain a committee, to be known as the Rare Dis-
4
ease and Condition Drug Advisory Committee (in this sec-
5
tion referred to as the ‘Advisory Committee’). 
6
‘‘(b) DUTY
OF COMMITTEE.—The Advisory Com-
7
mittee shall advise the Secretary on issues associated with 
8
development of therapies to treat rare diseases or condi-
9
tions. 
10
‘‘(c) SPECIFIC ISSUES.—In advising the Secretary, 
11
the Advisory Committee may address issues including— 
12
‘‘(1) modified or new regulatory pathways to 
13
support review of therapies; 
14
‘‘(2) clinical trial design needs, including devel-
15
opment of innovative approaches to clinical trials; 
16
‘‘(3) qualifications of biomarkers or other drug 
17
development tools for use in reviews; 
18
‘‘(4) modified or new standards to support the 
19
review of already marketed drugs being evaluated 
20
for repurposing to treat a rare disease or condition; 
21
and 
22
‘‘(5) issues— 
23
‘‘(A) that pertain to an application for ap-
24
proval of a therapy to treat a rare disease or 
25
condition; and 
26
01:39 May 07, 2021
H1730
9 
•HR 1730 IH
‘‘(B) with respect to which a review divi-
1
sion has requested that the Advisory Committee 
2
provide advice. 
3
‘‘(d) MEMBERSHIP.— 
4
‘‘(1) IN
GENERAL.—The Advisory Committee 
5
shall consist of— 
6
‘‘(A) not more than 15 members appointed 
7
by the Secretary in accordance with paragraph 
8
(2); and 
9
‘‘(B) the nonvoting ex officio members 
10
under paragraph (3). 
11
‘‘(2) APPOINTED MEMBERS.— 
12
‘‘(A) 
SPECIAL
GOVERNMENT
EMPLOY-
13
EES.—Members of the Advisory Committee ap-
14
pointed pursuant to paragraph (1)(A) shall 
15
serve as special Government employees (as de-
16
fined in section 202(a) of title 18, United 
17
States Code). 
18
‘‘(B) ELIGIBILITY.—To be eligible for ap-
19
pointment pursuant to paragraph (1)(A), an in-
20
dividual shall— 
21
‘‘(i) be eligible to serve as special Gov-
22
ernment employee (as defined in section 
23
202(a) of title 18, United States Code); 
24
and 
25
01:39 May 07, 2021
H1730
10 
•HR 1730 IH
‘‘(ii) have expertise in the fields of 
1
public policy, law, regulatory policy, eco-
2
nomics, patient-focused product develop-
3
ment, or patient advocacy. 
4
‘‘(C) COMPOSITION.—Of the members of 
5
the Advisory Committee appointed pursuant to 
6
paragraph (1)(A)— 
7
‘‘(i) up to 10 shall be selected from 
8
among experts in the disciplines relevant to 
9
the activities of the Intercenter Institute 
10
on Rare Diseases and Conditions, to in-
11
clude at least one expert in each of— 
12
‘‘(I) rare disease product develop-
13
ment; 
14
‘‘(II) conducting clinical trials 
15
with respect to rare diseases and con-
16
ditions, including with respect to very 
17
small patient populations; 
18
‘‘(III) rare disease and condition 
19
natural history and related studies; 
20
‘‘(IV) 
health 
economics 
per-
21
taining to the development of medical 
22
products for rare diseases or condi-
23
tions; 
24
01:39 May 07, 2021
H1730
11 
•HR 1730 IH
‘‘(V) manufacturing and related 
1
needs associated with medical prod-
2
ucts for rare diseases or conditions; 
3
and 
4
‘‘(VI) patient experience data col-
5
lection; and 
6
‘‘(ii) up to 5 shall be selected from the 
7
public, to include— 
8
‘‘(I) at least 4 individuals who 
9
are representatives of the rare disease 
10
patient community; 
11
‘‘(II) at least one individual who 
12
is directly impacted by a rare disease 
13
or condition; and 
14
‘‘(III) at least one person who 
15
serves as a family caregiver to a per-
16
son diagnosed with a rare disease or 
17
condition. 
18
‘‘(3) NONVOTING EX OFFICIO MEMBERS.—The 
19
nonvoting ex officio members of the Advisory Com-
20
mittee under paragraph (1)(B) shall consist of the 
21
following: 
22
‘‘(A) The Secretary (or the Secretary’s 
23
designee). 
24
01:39 May 07, 2021
H1730
12 
•HR 1730 IH
‘‘(B) The Director of the Intercenter Insti-
1
tute on Rare Diseases and Conditions. 
2
‘‘(C) The Director of the Center for Bio-
3
logics Evaluation and Research (or the Direc-
4
tor’s designee). 
5
‘‘(D) The Director of the Center for Drug 
6
Evaluation and Research (or the Director’s des-
7
ignee). 
8
‘‘(E) The Director of the Center for De-
9
vices and Radiological Health (or the Director’s 
10
designee). 
11
‘‘(F) The Director of the National Center 
12
for the Advancing Translational Sciences of the 
13
National Institutes of Health (or the Director’s 
14
designee). 
15
‘‘(G) The Administrator of the Centers for 
16
Medicare & Medicaid Services (or the Adminis-
17
trator’s designee). 
18
‘‘(H) Any additional officers or employees 
19
of the Department of Health and Human Serv-
20
ices as the Secretary determines necessary for 
21
the Advisory Committee to effectively carry out 
22
its functions. 
23
01:39 May 07, 2021
H1730
13 
•HR 1730 IH
‘‘(4) CHAIR.—The Chair of the Advisory Com-
1
mittee shall be the Director of the Intercenter Insti-
2
tute for Rare Diseases and Conditions. 
3
‘‘(5) TERMS.— 
4
‘‘(A) MEMBERS.— 
5
‘‘(i) IN
GENERAL.—The term of a 
6
member of the Advisory Committee ap-
7
pointed pursuant to paragraph (1)(A) shall 
8
be 4 years, except that any member ap-
9
pointed to fill a vacancy in an unexpired 
10
term shall be appointed for the remainder 
11
of that term. 
12
‘‘(ii) CONTINUED SERVICE.—A mem-
13
ber appointed pursuant to paragraph 
14
(1)(A) may continue serving as a member 
15
of the Advisory Committee for up to 180 
16
days after the expiration of that member’s 
17
term if a successor has not been appointed. 
18
‘‘(B) REAPPOINTMENT.—A member of the 
19
Advisory Committee who has been appointed 
20
pursuant to paragraph (1)(A) for a term of 4 
21
years may not be reappointed to serve as a 
22
member of the Advisory Committee before the 
23
date that is 2 years after the date of expiration 
24
of that member’s term. 
25
01:39 May 07, 2021
H1730
14 
•HR 1730 IH
‘‘(e) QUORUM.—A majority of the appointed mem-
1
bers of the Advisory Committee shall constitute a quorum 
2
for the conduct of business.’’. 
3
SEC. 5. GRANTS AND CONTRACTS FOR DEVELOPMENT OF 
4
DRUGS FOR RARE DISEASES AND CONDI-
5
TIONS. 
6
(a) AUTHORITY OF SECRETARY.—Section 5(a) of the 
7
Orphan Drug Act (21 U.S.C. 360ee(a)) is amended— 
8
(1) in paragraph (2), by striking ‘‘and’’ at the 
9
end; and 
10
(2) by inserting before the period at the end ‘‘, 
11
and (4) developing practices pertaining to the chem-
12
istry, manufacturing, regulatory approval of, and 
13
controls of individualized therapies or therapies to 
14
treat very small populations’’. 
15
(b) ALTITUDE PROGRAM.—In supporting grants 
16
and contracts under section 5(a)(4) of the Orphan Drug 
17
Act, as added by subsection (a), the Secretary of Health 
18
and Human Services shall consult with the Director of the 
19
Intercenter Institute on Rare Diseases and Conditions re-
20
garding the Accelerating Lifesavings Therapies in Treat-
21
ing Ultra-rare Disease Entities Program established under 
22
section 529B(b) of the Federal Food, Drug, and Cosmetic 
23
Act, as added by section 3(c) of this Act, to— 
24
01:39 May 07, 2021
H1730
15 
•HR 1730 IH
(1) identify the regulatory science and related 
1
challenges and needs associated with developing indi-
2
vidualized therapies or therapies to treat very small 
3
patient populations; and 
4
(2) support research to address such challenges. 
5
Æ 
01:39 May 07, 2021
H1730
